The US FDA has approved Mesoblast's Ryoncil (remestemcel-L-rknd) for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months and older. …
FDA approves Mesoblast's cell therapy to treat steroid-refractory acute graft-versus-host disease
December 19, 2024 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
Australia, the US, and their different choices about health system trade-offs
April 17, 2026 - - Latest News -
Why hospitals, and not medicines, dominate America’s health spending gap
April 17, 2026 - - Latest News -
New strategic alliance for Biointelect aims to fast track life sciences innovation
April 17, 2026 - - Latest News -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News -
Why US health spending looks much higher than it really is
April 16, 2026 - - Latest News -
Pharmacy prescribing reform signals shift in NSW primary care with Victoria to follow
April 15, 2026 - - Latest News